Newsroom

HILLSBORO, Oregon--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ : LSCC), leader dans le domaine des semi-conducteurs programmables à faible consommation, a annoncé aujourd’hui avoir été sélectionnée comme « Entreprise publique la plus respectée dans le secteur des semi-conducteurs » lors des 2025 Global Semiconductor Alliance (GSA) Awards. Les GSA Awards récompensent les entreprises qui ont fait preuve d’excellence par leur succès, leur vision, leur stratégie et leurs opportunités futures dan...

HILLSBORO, Oregon--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ: LSCC), leader nel settore dei dispositivi programmabili a basso consumo di potenza, oggi ha annunciato di essere stata selezionata come “Società pubblica di dispositivi a semiconduttori più rispettata” in occasione dei 2025 Global Semiconductor Alliance (GSA) Award, che vengono conferiti alle imprese che hanno dimostrato eccellenza attraverso il successo conseguito, la visione, la strategia e le opportunità sfruttabili nel setto...

HILLSBORO, Oregon--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ: LSCC), Marktführer im Bereich energieeffizienter programmierbarer Anwendungen, gab heute bekannt, dass das Unternehmen bei den 2025 Global Semiconductor Alliance (GSA) Awards zum „angesehensten börsennotierten Halbleiterunternehmen" gekürt wurde. Mit den GSA Awards werden Unternehmen ausgezeichnet, die durch Erfolg, Vision, Strategie und Zukunftschancen in der Branche Spitzenleistungen erzielt haben, was durch die Abstimmung der...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate du...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio today announced new data presented on its lead investigational allogeneic T-cell immunotherapy, Orca-T, at the 67th ASH Annual Meeting....

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Results from two arms of the EPCORE® NHL-2 trial, evaluating first-line, fixed-treatment dur...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. The results were presented by Ionis Pharmaceuticals...

MINNEAPOLIS--(BUSINESS WIRE)--New research from NMDP, a global nonprofit leader in cell therapy, and conducted by CIBMTR® (Center for International Blood and Marrow Transplant Research®) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla., demonstrates that patients receiving allogeneic transplantation using more deeply mismatched unrelated donors (MMUD), followed by post-transplant chemotherapy, can achieve outcomes comparable to those receiving tran...

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced a presentation of interim Phase 2 clinical data on RLS-0071 (pegtarazimod) for the treatment of acute graft-versus-host disease (aGvHD) at the 67th American Society of Hematology (ASH) Annual Meeting. The new findings will be presented i...

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets sub...